메뉴 건너뛰기
American Journal of Therapeutics
Volumn 16, Issue 1, 2009, Pages 68-70
Successful treatment of refractory idiopathic hypereosinophilic syndrome with etoposide
Author keywords

Etoposide; Idiopathic hypereosinophilic syndrome; Imatinib; Myeloproliferative disorder
Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; HYDROXYUREA; IMATINIB; PREDNISONE; VINCRISTINE; WARFARIN;
EID: 60249103763     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318175d12d     Document Type: Article
Times cited : (2)
References (14)
  • 1
    • 0014299959 scopus 로고
    • The hypereosinophilic syndromes
    • Hardy WR, Anderson RE. The hypereosinophilic syndromes. Ann Intern Med. 1968;68:1220-1229.
    • (1968) Ann Intern Med , vol.68 , pp. 1220-1229
    • Hardy, W.R.1    Anderson, R.E.2
  • 2
    • 0016430025 scopus 로고
    • The hypereosmophilic syndrome: Analysis of fourteen cases with review of literature
    • Chusid MJ, Dale DC, West BC, et al. The hypereosmophilic syndrome: analysis of fourteen cases with review of literature. Medicine. 1975;54:1-27.
    • (1975) Medicine , vol.54 , pp. 1-27
    • Chusid, M.J.1    Dale, D.C.2    West, B.C.3
  • 3
    • 0038315443 scopus 로고    scopus 로고
    • The hyper- eosinophilic syndrome revisited
    • Rouffosse M, Cogan E, Goldman M, et al. The hyper- eosinophilic syndrome revisited. Annu Rev Med. 2003;54: 169-184.
    • (2003) Annu Rev Med , vol.54 , pp. 169-184
    • Rouffosse, M.1    Cogan, E.2    Goldman, M.3
  • 4
    • 0024345311 scopus 로고
    • Prognostic factors of hypereosinophilic syndrome. Study of 40 cases
    • in French
    • Lefebvre C, Beltry O, Degoulete P, et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases [in French]. Ann Med Interne. 1989;140:253-257.
    • (1989) Ann Med Interne , vol.140 , pp. 253-257
    • Lefebvre, C.1    Beltry, O.2    Degoulete, P.3
  • 5
    • 0028323393 scopus 로고
    • The idiopathic hypereosinophilic syndrome
    • Waller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.
    • (1994) Blood , vol.83 , pp. 2759-2779
    • Waller, P.F.1    Bubley, G.J.2
  • 6
    • 0038386031 scopus 로고    scopus 로고
    • Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
    • Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391-3397.
    • (2003) Blood , vol.101 , pp. 3391-3397
    • Pardanani, A.1    Reeder, T.2    Porrata, L.F.3
  • 7
    • 0344987881 scopus 로고    scopus 로고
    • A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
    • Cools J, De Angelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
    • (2003) N Engl J Med , vol.348 , pp. 1201-1214
    • Cools, J.1    De Angelo, D.J.2    Gotlib, J.3
  • 8
    • 34248631981 scopus 로고    scopus 로고
    • Idiopathic hypereosinophilic syndrome with skull base involvement
    • Bettineni ML, Galetta SL, Oh J, et al. Idiopathic hypereosinophilic syndrome with skull base involvement. Am J Neuroradiol. 2007;28:971-973.
    • (2007) Am J Neuroradiol , vol.28 , pp. 971-973
    • Bettineni, M.L.1    Galetta, S.L.2    Oh, J.3
  • 9
    • 0019966379 scopus 로고
    • NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations
    • Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med. 1982;97:78-92.
    • (1982) Ann Intern Med , vol.97 , pp. 78-92
    • Fauci, A.S.1    Harley, J.B.2    Roberts, W.C.3
  • 10
    • 0035823530 scopus 로고    scopus 로고
    • Case report: Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate
    • Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med. 2001;3:9.
    • (2001) Med Gen Med , vol.3 , pp. 9
    • Schaller, J.L.1    Burkland, G.A.2
  • 11
    • 0037018763 scopus 로고    scopus 로고
    • Treatment of hypereosinophilic syndrome with imatinib mesylate
    • Gleich GJ, Leiferman KM, Pardanani A, et al. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet. 2002;359:1577-1578.
    • (2002) Lancet , vol.359 , pp. 1577-1578
    • Gleich, G.J.1    Leiferman, K.M.2    Pardanani, A.3
  • 12
    • 10744228476 scopus 로고    scopus 로고
    • Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
    • Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101:4714-4716.
    • (2003) Blood , vol.101 , pp. 4714-4716
    • Cortes, J.1    Ault, P.2    Koller, C.3
  • 13
    • 0025755974 scopus 로고
    • Successful long- term control of idiopathic hypereosinophilic syndrome with etoposide
    • Smit AJ, van Essen LH, de Vries EG, et al. Successful long- term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer. 1991;67:2826-2827.
    • (1991) Cancer , vol.67 , pp. 2826-2827
    • Smit, A.J.1    van Essen, L.H.2    de Vries, E.G.3
  • 14
    • 0028605947 scopus 로고
    • Etoposide for treating hypereosinophilic syndrome
    • Bourrat E, Lebbe C, Calvo F, et al. Etoposide for treating hypereosinophilic syndrome. Ann Int Med. 1994;121: 899-900.
    • (1994) Ann Int Med , vol.121 , pp. 899-900
    • Bourrat, E.1    Lebbe, C.2    Calvo, F.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.